You are here: Industry Insights > Scancell

News List

Lindy Durrant appointed CEO of Scancell firstwordpharma
July 29, 2021
Scancell Holdings plc (AIM: SCLP) is pleased to announce that Professor Lindy Durrant, founder, Board Director and Chief Scientific Officer of Scancell has been appointed Chief Executive Officer of Scancell Holdings plc with immediate effect.
Scancell picks lead COVID-19 vaccine candidate pharmatimes
December 21, 2020
UK-based Scancell Holdings has selected a lead COVID-19 vaccine candidate – SN14 – to advance through further development and into clinical trials.
Scancell receives funding for COVID-19 vaccine development pharmatimes
August 27, 2020
Scancell Holdings has secured funding of around £2 million from Innovate UK to initiate a Phase I clinical trial of an experimental SARS-CoV-2 vaccine.
Scancell to develop DNA vaccine candidate against Covid-19 pharmaceutical-technology
April 30, 2020
Immunotherapies developer Scancell has launched a research programme focused on the development of a DNA vaccine candidate to protect from Covid-19.
Scancell kicks off COVID-19 vaccine development pharmatimes
April 24, 2020
Scancell has initiated a research programme to develop a vaccine for COVID-19.
Scancell, CR UK publish joint vaccine update pharmatimes
May 28, 2019
Scancell Holdings has announced that its ImmunoBody vaccine, SCIB2, is to be administered using a new nanoparticle formulation in a planned Phase I/II clinical trial.
Scancell appoints Head of Research and Head of Manufacturing firstwordpharma
January 22, 2019
Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer, today announces the appointment of Dr Samantha Paston as Head of Research and Dr Adrian Parry as Head of Manufacturing.